NCT04217317 2025-05-02
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Wake Forest University Health Sciences
Phase 2 Terminated
Clinical Trials
5 trialsNCT03374852 2025-04-29
CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Thomas Jefferson University
Phase 2 Withdrawn
NCT03793140 2025-04-16
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05854966 2024-09-19
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting